It consists of two antibodies-casirivimab and imdevimab. Antibody mixtures are mixtures of two or more unique biological agents that act like human antibodies against infection. The antibody mixture is suitable for mild to moderate coronavirus patients over 12 years old. And weight should not be less than 40 kg.
This will reduce the likelihood of these patients being hospitalized by 70% while eliminating the need for oxygen assistance. “In India, the supply of antibody mixtures (casirivimab and imdevimab) can help reduce hospital stays, reduce the burden on the healthcare system, and play a key role in treating high-risk patients before their condition worsens,” Roche CEO.
Umang Vohra, general manager and CEO of Cipla, a pharmaceutical company in India, said the company hopes to use its “strong Indian marketing and sales capabilities to provide a broader and fairer opportunity for this innovative treatment in India.”
The drug will be sold in the country. India provided the first batch of 100,000 containers through the Cipla distribution network, benefiting 200,000 patients because each container can treat 2 patients.
When stored between 2°C and 8°C to drink a cocktail, the vial opened for the first patient dose can be used for the second patient dose within 48 hours.It has also obtained EUA certification in the United States and several EU countries.